A Phase 1, Randomized, Open-label, Parallel-group, Drug-drug Interaction Study to Evaluate the Effect of Antiemetic Medication on the Pharmacokinetics of AMG 133 in Participants Living With Overweight or Obesity
Latest Information Update: 06 Jan 2026
At a glance
- Drugs Maridebart cafraglutide (Primary) ; Ondansetron (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Amgen
Most Recent Events
- 06 Jan 2026 New trial record